title: Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.
abstract: BACKGROUND
  Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib.
  
  
  METHODS
  Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment.
  
  
  RESULTS
  The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001).
  
  
  CONCLUSIONS
  LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.
authors.affiliation: Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic fiala.o@centrum.cz.
authors.forename: Ondrej
authors.initials: O
authors.lastname: Fiala
authors.affiliation: Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
authors.forename: Milos
authors.initials: M
authors.lastname: Pesek
authors.affiliation: Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
authors.forename: Jindrich
authors.initials: J
authors.lastname: Finek
authors.affiliation: Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
authors.forename: Ondrej
authors.initials: O
authors.lastname: Topolcan
authors.affiliation: Istitute of Clinical Biochemistry and Hematology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Racek
authors.affiliation: Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
authors.forename: Martin
authors.initials: M
authors.lastname: Svaton
authors.affiliation: Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
authors.forename: Radek
authors.initials: R
authors.lastname: Kucera
authors.affiliation: Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic Department of Analytical Chemistry, Faculty of Sciences, Charles University in Prague, Prague, Czech Republic.
authors.forename: Marek
authors.initials: M
authors.lastname: Minarik
authors.affiliation: Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic.
authors.forename: Lucie
authors.initials: L
authors.lastname: Benesova
authors.affiliation: Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
authors.forename: Zbynek
authors.initials: Z
authors.lastname: Bortlicek
authors.affiliation: Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
authors.forename: Renata
authors.initials: R
authors.lastname: Chloupkova
authors.affiliation: Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
authors.forename: Alexandr
authors.initials: A
authors.lastname: Poprach
authors.affiliation: Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
authors.forename: Tomas
authors.initials: T
authors.lastname: Buchler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000188:drug therapy; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000069347:Erlotinib Hydrochloride; D007770:L-Lactate Dehydrogenase
keywords: EGFR-TKI; LDH; Lactate dehydrogenase; NSCLC; biomarker; erlotinib; lung cancer; prediction